Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

Inclusion Criteria: * Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck, renal, breast, lung, ovary, liver) * Patients must have measurable disease (1.0 cm or greater) by computed tomography (CT) scan * Have an estimated glomerular filtration rate (eGFR) (using the Cockcroft-Gault equation) of more than 60 mL/min * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment * Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * History of prior myocardial infarction or arrhythmia * History of any condition deemed by the principal investigator to be a contraindication to B-WARM therapy (e.g., skin reaction, dysregulation of thermoregulation, etc) * All patients with transdermal patches (e.g.; fentanyl, Lidoderm, scopolamine, etc) * Pregnant or nursing female patients * Unwilling or unable to follow protocol requirements * Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive B-WARM * Received an investigational agent within 30 days prior to enrollment * Received any systemic therapy within 21 days prior to planned B-WARM therapy * Patients may be enrolled on study but at least 21 days should elapse prior to date of B-WARM therapy * Patients should not have either CT scanning or B-WARM if they have a fever at the time * Fever should be worked up and treated as appropriate * Patients should be afebrile for 24 hours prior to scanning or B-WARM therapy